JP5563988B2 - 癌のマーカーとしてのセプラーゼ - Google Patents

癌のマーカーとしてのセプラーゼ Download PDF

Info

Publication number
JP5563988B2
JP5563988B2 JP2010537302A JP2010537302A JP5563988B2 JP 5563988 B2 JP5563988 B2 JP 5563988B2 JP 2010537302 A JP2010537302 A JP 2010537302A JP 2010537302 A JP2010537302 A JP 2010537302A JP 5563988 B2 JP5563988 B2 JP 5563988B2
Authority
JP
Japan
Prior art keywords
cancer
seprase
marker
activity
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010537302A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011506941A5 (https=
JP2011506941A (ja
Inventor
ロリンガー，ウォルフガング
カール，ヨハン
コーチャン，ジャレマ，ピーター
レスラー，マルクス
タッケ，ミヒァエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07023897A external-priority patent/EP2071337A1/en
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2011506941A publication Critical patent/JP2011506941A/ja
Publication of JP2011506941A5 publication Critical patent/JP2011506941A5/ja
Application granted granted Critical
Publication of JP5563988B2 publication Critical patent/JP5563988B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57565—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen [CEA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96402—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals
    • G01N2333/96405—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general
    • G01N2333/96408—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general with EC number
    • G01N2333/96411—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oncology (AREA)
JP2010537302A 2007-12-10 2008-12-08 癌のマーカーとしてのセプラーゼ Expired - Fee Related JP5563988B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07023897.7 2007-12-10
EP07023897A EP2071337A1 (en) 2007-12-10 2007-12-10 Seprase as a marker for cancer
EP08015310 2008-08-29
EP08015310.9 2008-08-29
PCT/EP2008/010385 WO2009074275A1 (en) 2007-12-10 2008-12-08 Seprase as a marker for cancer

Publications (3)

Publication Number Publication Date
JP2011506941A JP2011506941A (ja) 2011-03-03
JP2011506941A5 JP2011506941A5 (https=) 2011-10-06
JP5563988B2 true JP5563988B2 (ja) 2014-07-30

Family

ID=40373548

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010537302A Expired - Fee Related JP5563988B2 (ja) 2007-12-10 2008-12-08 癌のマーカーとしてのセプラーゼ

Country Status (14)

Country Link
US (1) US8980573B2 (https=)
EP (1) EP2223115B1 (https=)
JP (1) JP5563988B2 (https=)
KR (1) KR101202220B1 (https=)
CN (1) CN101896818B (https=)
AT (1) ATE524740T1 (https=)
AU (1) AU2008335855B2 (https=)
BR (1) BRPI0820793A2 (https=)
CA (1) CA2706115A1 (https=)
DK (1) DK2223115T3 (https=)
ES (1) ES2372442T3 (https=)
MX (1) MX2010004671A (https=)
PL (1) PL2223115T3 (https=)
WO (1) WO2009074275A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8213005B2 (en) 2003-07-22 2012-07-03 King Saud University Method for discriminating between benign and malignant prostate tumors
EP2297581B1 (en) * 2008-07-03 2013-04-03 F. Hoffmann-La Roche AG Asc as a marker for lung cancer
WO2011075744A1 (en) 2009-12-20 2011-06-23 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2011213684B2 (en) 2010-02-05 2014-11-20 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2012054732A2 (en) * 2010-10-20 2012-04-26 Rush University Medical Center Lung cancer tests
WO2012123299A1 (en) 2011-03-11 2012-09-20 Roche Diagnostics Gmbh Asc as marker for chronic obstructive pulmonary disease (copd)
WO2012123293A1 (en) * 2011-03-11 2012-09-20 Roche Diagnostics Gmbh Seprase as marker for chronic obstructive pulmonary disease (copd)
CN102435748B (zh) * 2011-11-25 2014-07-16 广东药学院 一种双抗夹心酶联免疫检测试剂盒及其制备方法
US10935548B2 (en) 2011-12-08 2021-03-02 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
NZ703411A (en) 2012-06-27 2017-09-29 Berg Llc Use of markers in the diagnosis and treatment of prostate cancer
WO2014072465A1 (en) 2012-11-09 2014-05-15 Roche Diagnostics Gmbh In vitro capture and analysis of circulating tumor cells
WO2014085826A2 (en) * 2012-11-30 2014-06-05 Applied Proteomics, Inc. Method for evaluation of presence of or risk of colon tumors
EP3361255B1 (en) 2013-01-17 2020-03-11 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9753037B2 (en) 2013-03-15 2017-09-05 Rush University Medical Center Biomarker panel for detecting lung cancer
CN103267852B (zh) * 2013-05-15 2015-03-25 中国医学科学院北京协和医院 成纤维激活蛋白α在制备胰腺癌预后试剂盒中的用途
KR101619122B1 (ko) 2013-08-14 2016-05-10 연세대학교 산학협력단 탈메틸화 의존적 ａｓｃ 발현을 촉진시켜서 대장암 종양세포의 사멸감수성을 증진시키는 항암제 병용 투여용 후보물질의 스크리닝 방법
US10365281B2 (en) 2013-12-09 2019-07-30 Rush University Medical Center Biomarkers of rapid progression in advanced non-small cell lung cancer
PL230661B1 (pl) * 2014-01-29 2018-11-30 Centrum Onkologii Inst Im Marii Sklodowskiej Curie Oddzial W Gliwicach Metoda predykcyjna in vitro do przewidywania i/lub wykluczenia obecnosci raka pluc, zastosowanie in vitro metody predykcyjnej oraz zestaw testowy do wykrywania in vitro raka pluc
EP2916134B1 (en) * 2014-03-05 2017-08-16 Roche Diagnostics GmbH Use of Seprase for differential diagnosis of acute dyspnea
SG10202012249YA (en) 2014-12-08 2021-01-28 Berg Llc Use of markers including filamin a in the diagnosis and treatment of prostate cancer
WO2016146174A1 (en) * 2015-03-17 2016-09-22 Biontech Ag Compositions and methods for diagnosis and treatment of cancer
WO2016164815A1 (en) 2015-04-10 2016-10-13 Applied Proteomics, Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
CA3029926C (en) * 2016-07-25 2023-01-03 Shizuoka Prefecture Diagnostic biomarker for extrahepatic bile duct cancer, intrahepatic bile duct cancer or gallbladder cancer
CN116474108A (zh) 2016-12-14 2023-07-25 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗
DE102017010455A1 (de) * 2017-06-13 2018-12-13 Forschungszentrum Jülich GmbH Verfahren zum Nachweis von Aggregaten biotherapeutischer Substanzen in einer Probe
WO2019050275A1 (ko) * 2017-09-05 2019-03-14 (주)온코태그디아그노스틱 메티오닐 -티알엔에이 합성효소를 이용한 췌장암 진단 방법 및 이를 이용한 췌장암 진단 키트
WO2022007283A1 (zh) * 2020-07-08 2022-01-13 深圳霁因生物医药转化研究院 用于诊断fap表达异常相关疾病的试剂盒、方法及计算机可读存储介质

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
AU2004286307A1 (en) * 2003-10-31 2005-05-12 Vitatex, Inc. Blood test prototypes and methods for the detection of circulating tumor and endothelial cells
WO2007001420A2 (en) * 2004-10-22 2007-01-04 Genencor International, Inc. Isolating human antibodies
EP1760076A1 (en) * 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
WO2007100374A2 (en) * 2005-12-19 2007-09-07 Trustees Of Tufts College Soft protease inhibitors and pro-soft forms thereof

Also Published As

Publication number Publication date
MX2010004671A (es) 2010-05-27
CA2706115A1 (en) 2009-06-18
EP2223115A1 (en) 2010-09-01
US20100240081A1 (en) 2010-09-23
AU2008335855B2 (en) 2012-08-30
PL2223115T3 (pl) 2012-02-29
KR101202220B1 (ko) 2012-11-16
AU2008335855A1 (en) 2009-06-18
WO2009074275A1 (en) 2009-06-18
CN101896818A (zh) 2010-11-24
ES2372442T3 (es) 2012-01-19
US8980573B2 (en) 2015-03-17
JP2011506941A (ja) 2011-03-03
KR20100091212A (ko) 2010-08-18
DK2223115T3 (da) 2011-12-12
CN101896818B (zh) 2016-01-20
ATE524740T1 (de) 2011-09-15
HK1150884A1 (zh) 2012-01-13
BRPI0820793A2 (pt) 2015-06-16
EP2223115B1 (en) 2011-09-14

Similar Documents

Publication Publication Date Title
JP5563988B2 (ja) 癌のマーカーとしてのセプラーゼ
JP5312684B2 (ja) 癌のマーカーとしてのｄｐｐｉｖ／セプラーゼの使用
JP5591711B2 (ja) 結腸直腸癌のためのマーカーパネル
JP5731488B2 (ja) 癌のマーカーとしてのセセルニン‐１
US10815517B2 (en) Use of DPPIV/seprase as a marker for cancer
EP2071337A1 (en) Seprase as a marker for cancer
JP4981133B2 (ja) 肺癌用マーカーとしてのｎｎｍｔの使用
JP5681183B2 (ja) 癌マーカーとしてのフラップエンドヌクレアーゼ−１
CN102439455B (zh) 作为肺癌标志物的cybp
HK1150884B (en) Seprase as a marker for cancer
HK1169168B (en) Use of dppiv/seprase as a marker for cancer
HK1151093A (en) Marker panel for colorectal cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110816

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110816

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131017

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140603

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140613

R150 Certificate of patent or registration of utility model

Ref document number: 5563988

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees